-

12:49:19 PM

CYAD Stock News

CYAD - Celyad Oncology

03/17/23 5:01 PM

Nasdaq : CYAD

earningslow float

Celyad Oncology to announce full year 2022 financial results and host conference call

Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the

RHEA-AI

neutral

03/15/23 2:00 AM

Nasdaq : CYAD

low float

Celyad Oncology announces non-cash impairment

Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced a non-cash

RHEA-AI

neutral

03/01/23 1:00 AM

Nasdaq : CYAD

low float

Celyad Oncology: Letter to Shareholders

Also, Celyad transitioned from autologous to allogeneic approaches, which changed our company dynamic. A re-organization plan was put in place in June, under the leadership of Michel Lussier, who stepped down as chairman of the board and assumed the position of CEO ad interim, succeeding our then-CEO and CFO, Filippo Petti. Hilde Windels, a member of our board...

RHEA-AI

neutral

03/01/23 1:00 AM

Nasdaq : CYAD

low float

REPEAT -- Celyad Oncology SA - Letter to Shareholders

The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs had clear potential, as we

RHEA-AI

neutral

02/28/23 11:16 AM

Nasdaq : CYAD

low float

Celyad Oncology SA - Letter to Shareholders

The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs had clear potential, as we

RHEA-AI

neutral

02/09/23 1:00 AM

Nasdaq : CYAD

clinical triallow float

Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01

Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces the

RHEA-AI

neutral

02/03/23 1:00 AM

Nasdaq : CYAD

low float

Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook

Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property The company is now prioritizing internal discovery endeavors to tackle the major

RHEA-AI

neutral

12/21/22 1:00 AM

Nasdaq : CYAD

low float

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides an update on

RHEA-AI

neutral

11/10/22 1:01 AM

Nasdaq : CYAD

earningslow float

Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discovery Clinical updates expected by end of year for the Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for

RHEA-AI

neutral

10/12/22 1:00 AM

Nasdaq : CYAD

low float

Celyad Oncology Provides Strategic Update

Celyad Oncology, a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, today provided an update on its strategic business model, clinical trial programs, and the related operational and organizational steps and cost-saving measures that it will undertake. The Company’ s U.S. patents...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next